Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital dischar
- PDF / 883,733 Bytes
- 4 Pages / 595.276 x 793.701 pts Page_size
- 66 Downloads / 136 Views
cline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge 12†
2†
12†
2
3
4
Huan Ma , Dan Zhao , Weihong Zeng , Yunru Yang , Xiaowen Hu , Peigen Zhou , 1,5,6 7,8 1,5,6* 1,2,9* Jianping Weng , Linzhao Cheng , Xueying Zheng & Tengchuan Jin 1
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, 2
China; Hefei National Laboratory for Physical Sciences at Microscale, Laboratory of Structural Immunology, CAS Key Laboratory of Innate
Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China; 3 Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Department of Statistics, University of Wisconsin-Madison, Madison, WI 53706, USA; 5 Joint Laboratory of Public Health, University of Science and Technology of China and Health Commission of Anhui Province, Hefei 230026, China; 6 Clinical Research Hospital (Hefei) of Chinese Academy of Science, Hefei 230001, China; 7 Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei Anhui 230026, China; 8 Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 9 CAS Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China 4
Received July 13, 2020; accepted August 26, 2020; published online August 28, 2020
Citation:
Ma, H., Zhao, D., Zeng, W., Yang, Y., Hu, X., Zhou, P., Weng, J., Cheng, L., Zheng, X., and Jin, T. (2020). Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge. Sci China Life Sci 63, https://doi.org/10.1007/s11427-020-18050
Dear editor, The 2019 novel coronavirus (later renamed as SARS-CoV-2 in February 2020) infected over 12 million people globally by early July 2020, causing mild to severe COVID-19 in millions. Monitoring the levels of antibodies such as immunoglobin (Ig) G, M and A that are specific to SARS-CoV2 and present in the blood provides not only an alternative method for diagnosing SARS-CoV-2 infection (including asymptomatic carriers), but also a simple way to monitor immune responses in convalescent patients or after vaccination. A high and persistent level of antibodies specific to SARS-CoV-2, especially those that can bind to and neutralize the virus, would be a strong indication that an im†Contributed equally to this work *Corresponding authors (Tengchuan Jin, email: [email protected]; Xueying Zheng, email: [email protected])
munized host could resist to SRAS-CoV-2 infection. Currently, there are no effective drugs to specifically prevent or cure SARS-CoV-2 infection; therefore, host immune responses and antibody-based therapeutics will continue to play important roles in combating and later preventing COVID-19. We pre
Data Loading...
